Salubris Biotherapeutics Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

Salubris Biotherapeutics focuses on the discovery and global development of novel biologic therapies. As a subsidiary of Salubris Pharmaceuticals, a China-based company, it reflects the parent group’s emphasis on innovation and expanding into international markets. Headquartered in Gaithersburg, Maryland, the company was founded in August 2016 to pursue biotech research in the biologics space. 

SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, drawing on more than 150 research scientists and manufacturing capability up to 2000 liters. In 2022, the company launched JK07, an antibody fusion protein for heart failure, with phase 1b data indicating clinically meaningful improvements in ejection fraction. In 2026, it announced expansion-cohort data for JK06, a 5T4-targeted antibody-drug conjugate, at the American Association for Cancer Research conference.

Sign up for free to view info

Company overview Employee directory